methadone / Generic mfg. - LARVOL DELTA

A decade of change: trends in drug and alcohol use in Iran (2010-2019). (PubMed, BMC Public Health) - "The increasing prevalence of drugs and alcohol is alarming. Understanding these trends is essential for shaping public health policies and interventions."

Journal

Treatment Outcomes in a Specialized Opioid Maintenance Program for Prescription Opioid Use Disorder in Israel. (PubMed, Subst Abuse Rehabil) - "Overall, 42.9% used fentanyl: 44.4% of those on methadone, 42.1% on buprenorphine, and 42.9% on the injectable formulation. Positive treatment outcomes were observed in this specific population, particularly among those treated with methadone or injectable buprenorphine, but future follow-up and a larger sample are needed. Physicians' education is necessary to achieve more accurate referrals."

Journal • Addiction (Opioid and Alcohol) • Pain • Substance Abuse

Who are we reaching? Identifying subgroups among individuals seeking help for opioid use disorder. (PubMed, Front Psychiatry) - "Individuals Primarily Using Opioids did not exhibit clearly distinctive patterns of service utilization and disproportionately reported methadone or other opioids as their main substances of use...Individuals with Multiple SUDs may benefit from more flexible OAT frameworks that accommodate work and family responsibilities. For Individuals Who Inject Drugs, integrated health and social services, combined with expanded harm reduction efforts (e.g., syringe exchange, testing opportunities for infectious diseases), may help reduce access barriers and effectively address their complex needs."

Journal • Addiction (Opioid and Alcohol) • CNS Disorders • Hepatitis C • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Psychiatry • Substance Abuse

The Association Between Receiving Medications for Opioid Use Disorder and Human Immunodeficiency Virus Testing: Findings From the Rural Opioid Initiative. (PubMed, J Addict Med) - "Recent HIV testing prevalence among this rural population of PWUD was low, given testing guidelines. Future research should explore ways to increase testing in rural drug treatment settings and whether there are differences by treatment setting type."

Journal • Addiction (Opioid and Alcohol) • CNS Disorders • Human Immunodeficiency Virus • Infectious Disease • Psychiatry • Substance Abuse

Slow-Release Oral Morphine vs Methadone for Opioid Use Disorder in the Fentanyl Era. (PubMed, JAMA Netw Open) - "Compared with methadone, SROM was associated with a slightly higher risk of treatment discontinuation and lower adherence but similar mortality risk. The findings suggest either medication may be appropriate if measures are in place to support retention."

Clinical • Journal • Observational data • Addiction (Opioid and Alcohol) • Substance Abuse

A Case of 7-Hydroxymitragynine Use Disorder Treated With Buprenorphine. (PubMed, J Addict Med) - "7-HMG is a widely available, largely unregulated, underrecognized substance with potency at the µ-opioid receptor that may increasingly concern clinicians and policymakers. Patients with 7-HMG use disorder may benefit from medication for opioid use disorder. More research is needed to characterize the effects of 7-HMG in humans and guide management."

Journal • Addiction (Opioid and Alcohol) • CNS Disorders • Depression • Psychiatry • Substance Abuse

Differences in anxiety, depression, and heart rate variability between patients with methamphetamine use disorder and heroin use disorder patients on methadone maintenance treatment. (PubMed, BMC Psychiatry) - No abstract available

Journal • CNS Disorders • Depression • Mood Disorders • Psychiatry

Methadone Dose and Patient-Directed Discharge in Hospitalized Patients With Opioid Use Disorder. (PubMed, JAMA Netw Open) - "In this study, higher cumulative doses of methadone during the first 48 hours of care were associated with substantial reductions in the incidence of PDD. These findings suggest that early and adequate treatment of withdrawal with methadone may be associated with reduced PDD among hospitalized patients with OUD in the fentanyl era."

Journal • Observational data • Retrospective data • Addiction (Opioid and Alcohol) • Substance Abuse

HIV viral non-suppression and drug resistance among persons who inject drugs on dolutegravir antiretroviral therapy in Kenya. (PubMed, medRxiv) - "We enrolled Kenyan PWID who had transitioned from an efavirenz ( EFV ) based regimen to tenofovir+lamivudine+DTG ( TLD ) ≥6 months prior, and measured plasma HIV RNA viral load ( VL ) every 6 months for 2 years...Among 250 participants, 125 were receiving methadone, 199 (79.6) reported heroin use, 70% were male, and median age was 39 years...While NNRTI resistance was common, DTG resistance mutations were rare. Improving viral suppression among PWID living with HIV will reduce transmission risks and improve clinical outcomes."

Journal • Human Immunodeficiency Virus • Infectious Disease

Contextual Influences on Naltrexone Sensitization During Daily Morphine Exposure. (PubMed, J Pharmacol Exp Ther) - "Tolerance to the effects of both μ- (morphine, heroin, buprenorphine, methadone) and κ-opioid (U50,488) agonists during daily chronic morphine also was evaluated. Low doses of naltrexone also have disruptive effects during opioid dependence. These studies show that the expression of naltrexone effects during opioid dependence is a product of both pharmacological and behavioral factors."

Journal • Addiction (Opioid and Alcohol)

Drug positivity, co-detection patterns, and demographic predictors in patients seeking substance use disorder treatment, United States, 2023. (PubMed, Addict Behav) - "This study highlights variations in substance presence and co-detection across 14 drug categories in SUD treatment patients, underscoring the need for tailored prevention and treatment strategies."

Journal

Latent classes of sleep deficiency and correlates among patients receiving methadone treatment: A longitudinal study. (PubMed, Addiction) - "Varieties of sleep deficiency compared with normal sleep appear to be associated with more severe psychological symptoms and pain interference with sleep among patients receiving methadone treatment and may serve as risk factors for substance use."

Journal • Observational data • CNS Disorders • Insomnia • Movement Disorders • Obstructive Sleep Apnea • Pain • Respiratory Diseases • Restless Legs Syndrome • Sleep Disorder • Substance Abuse

Improvements in substance use and social determinants of health associated with hepatitis C treatment initiation and sustained virologic response in opioid treatment programs. (PubMed, Addict Behav Rep) - "We used administrative and clinical trial outcome data from HCV-infected methadone-treated participants ( ) to evaluate changes in substance use and SDOH associated with HCV treatment initiation and SVR...Individual and regional-level subgroup differences could guide intervention implementation. HCV treatment initiation and SVR lead to improvements, not only in liver and infectious diseases outcomes, but in social and substance use factors."

Journal • CNS Disorders • Hepatitis C • Infectious Disease • Inflammation • Psychiatry • Substance Abuse

Comparison of naloxone, naltrexone, nalmefene, and methocinnamox for preventing and reversing the discriminative stimulus effects of buprenorphine and carfentanil in rats discriminating fentanyl from saline. (PubMed, J Pharmacol Exp Ther) - "MOR agonist medications for treating opioid use disorder include methadone and buprenorphine. SIGNIFICANCE STATEMENT: Buprenorphine, a μ opioid receptor (MOR) agonist used to treat opioid use disorder, can produce adverse effects that are reportedly more difficult to reverse with naloxone, compared with reversal of the effects of other MOR agonists. This study provides evidence for the potential utility of the MOR antagonist methocinnamox to reverse the adverse effects of buprenorphine by demonstrating the relatively greater potency of methocinnamox, compared with currently available MOR antagonists, to reverse the discriminative stimulus effects of buprenorphine and carfentanil."

Journal • Preclinical • Addiction (Opioid and Alcohol) • CNS Disorders • Depression • Psychiatry • Substance Abuse

Chronic tramadol abuse as a cause of serotonin syndrome. (PubMed, Toxicol Rep) - "Tramadol was discontinued and replaced with methadone. This case illustrates that chronic high-dose tramadol use alone may precipitate serotonin syndrome. Clinicians should remain alert to this potentially life-threatening complication, even in the absence of concomitant serotonergic medication."

Journal • Cardiovascular • Hypertension • Mood Disorders • Ophthalmology • Psychiatry

A RCT Using Methadone in the Management of Post-Operative Pain in Total Knee Replacement (clinicaltrials.gov) - P4 | N=192 | Not yet recruiting | Sponsor: AdventHealth

New P4 trial • Musculoskeletal Diseases • Orthopedics • Pain

Neurodevelopmental and Behavioral Outcomes at Two Years in Children Prenatally Exposed to Buprenorphine or Methadone in the ESC-NOW Trial (PAS 2026) - No abstract available

Clinical • Neurodevelopmental

Predicting and Preventing Adverse Maternal and Child Outcomes of Opioid Use Disorder in Pregnancy (clinicaltrials.gov) - P=N/A | N=100 | Recruiting | Sponsor: Ilana Hull | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Substance Abuse

HIV Pre-Exposure Prophylaxis Awareness among Individuals in Treatment for Opioid Use Disorder in the United States: A Cross-Sectional Study. (PubMed, AIDS Behav) - "Bivariate logistic regression showed that, compared to others, individuals who were older, African American/Black, and in methadone treatment less frequently reported PrEP awareness (p≤.018), while those who reported sex with a person who injects drugs, inpatient/day treatment, and self-help group attendance more frequently reported PrEP awareness (p≤.041). Increased education and outreach to PrEP eligible individuals in methadone and other opioid treatment programs appears warranted."

Journal • Observational data • Addiction (Opioid and Alcohol) • Human Immunodeficiency Virus • Infectious Disease • Substance Abuse

Deprescribing methadone for chronic non-cancer pain: management of withdrawal symptoms (PubMed, Ugeskr Laeger) - "Initial CT head was normal, while MRI confirmed bilateral thalamic and mesencephalic infarcts. This condition should be considered in patients with acute unexplained consciousness disturbance."

Journal • Cardiovascular • CNS Disorders • Oncology • Pain

Factors Associated With Opioid Agonist Treatment Engagement and Harm Reduction Service Use: Findings From the New South Wales Opioid Dependence Survey. (PubMed, Drug Alcohol Rev) - "Those not receiving OAT reported greater social instability, recent injecting drug use and drug-related harm. Variation in harm reduction service use suggests tailored strategies are needed to reach those outside OAT. These findings highlight the need for integrated, diverse strategies to address dependence-related harms."

Journal • Addiction (Opioid and Alcohol) • CNS Disorders • Mental Retardation • Psychiatry

Deprescribing methadone for chronic non-cancer pain: management of withdrawal symptoms (PubMed, Ugeskr Laeger) - "Withdrawal symptoms were managed through an individually tailored plan, supportive consultations with a nurse, and the use of clonidine. The patient regained function after deprescribing methadone. Deprescribing opioids can be managed through a patient-centered approach and close monitoring."

Journal • Oncology • Pain

Interactions between long-acting antiretrovirals and opioids: a call for clinical awareness. (PubMed, Clin Microbiol Rev) - "A comprehensive literature review was performed using PubMed and Google Scholar, along with data from the Liverpool HIV Drug Interactions Database, to evaluate pharmacokinetic interactions between LAA drugs, such as cabotegravir, rilpivirine, lenacapavir, and dapivirine, with opioids used in clinical settings, including morphine, tramadol, oxycodone, and codeine; medications for opioid use disorder (MOUD), such as methadone and buprenorphine; and the illicit opioids, including fentanyl and heroin. The review highlights key factors increasing DDI risk and discusses clinical considerations for managing preexposure prophylaxis (PrEP) or antiretroviral therapy (ART) in persons who use opioids. Lastly, it proposes research strategies for studying DDIs, including the use of animal models, physiologically based pharmacokinetic (PBPK) models, and clinical trials."

Journal • Review • Human Immunodeficiency Virus • Infectious Disease • Substance Abuse

Intraoperative Intravenous Methadone Utilization in Cardiac Surgery (SCCM 2026) - "Data collection included intravenous methadone dose, length of ICU stay, time on the vent, and 48-hour postoperative opioid medication doses recorded as oral morphine equivalents (OME). Preliminary data suggests that there is a small numerical difference in vent hours favoring no methadone, but a higher calculated OME in that same group. Findings warrant further study to determine statistical and clinical significance on postoperative quality measures and changes to current local practice."

Surgery • Cardiovascular

Evaluation of Dose-Dependent Association of Methadone to QTc Prolongation in Pediatric Patients (SCCM 2026) - "While receipt of methadone demonstrated a prolongation of QTc above baseline, we could not identify that increasing doses of methadone provided further prolongation to the QTc interval."

Clinical • Addiction (Opioid and Alcohol) • Cardiovascular • CNS Disorders • Nephrology • Palliative care • Pediatrics • Renal Disease • CYP3A4